Optimi Health Joins First Psychedelic Exchange Traded Fund

Optimi Health加入首只迷幻交易所交易基金

2021-07-20 23:00:40 CFN Media Group

本文共2245个字,阅读需6分钟

VANCOUVER, British Columbia, July 13, 2021 — Optimi Health Corp. , a vertically integrated developer of mushroom products is pleased to announce its inclusion in the first psychedelics Exchange Traded Fund . The ETF began trading on the Neo Exchange as of January 26, 2021. The ETF invests in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances. Optimi Health is one of currently twenty-three companies to have met the requirements of listing within the ETF. The ETF seeks to replicate, to the extent possible and net of expenses, the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly listed life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry. Currently, the ETF seeks to replicate the performance of the North American Psychedelics Index, net of expenses. Rebalancing of the North American Psychedelics Index occurs each calendar quarter. At those points, all stocks eligible for inclusion are generally re-weighted by their respective float market capitalization. Optimi Health received a 1.74% weighting at inclusion. The ETF is managed by Horizons ETF Management an innovative financial services company offering one of the largest suites of exchange traded funds in Canada. The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. Horizons ETFs has over $19 billion of assets under management and 95 ETFs listed on major Canadian stock exchanges. Horizons also brought the first cannabis ETF to market in 2017 and continues to lead the industry with ETFs in emerging industries. Optimi Health’s CEO Mike Stier states, “Inclusion into the ETF is a significant milestone for Optimi Health’s stakeholders. The recognition the Horizons ETF brings us is certainly advantageous to the Company and the increased visibility alone is a big plus, providing increased confidence and assurance to the newer investors. While the ETF brings additional exposure to potential new investors, it also generates value for existing shareholders. We are incredibly pleased to make this announcement today and look forward to capitalizing upon this outstanding opportunity as quickly as possible.” On Behalf of the Board of Directors, Optimi Health Corp. Mike Stier President, Chief Executive Officer and Director ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/. FOR FURTHER INFORMATION CONTACT: Investor Relations Email: [email protected] Phone: +1 (778) 930-1321 Web: https://optimihealth.ca/ FORWARD‐LOOKING STATEMENTS This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the Company’s potential Nasdaq listing, the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives. Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement. This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
2021年7月13日,不列颠哥伦比亚省温哥华--蘑菇产品垂直集成开发商Optimi Health Corp.很高兴宣布将其纳入第一只迷幻药交易所交易基金。该ETF于2021年1月26日开始在Neo交易所交易。 该ETF投资于迷幻药行业中从事涉及迷幻药及物质的合法活动的公司,并间接从这些公司获取收入。 Optimi Health是目前23家符合ETF上市条件的公司之一。ETF寻求在可能的范围内并扣除费用,复制一个市场指数的表现,该指数旨在提供对一篮子北美上市生命科学公司的表现的敞口,这些公司在迷幻药行业有重大业务活动或对迷幻药行业有重大敞口。目前,该ETF寻求复制北美迷幻指数(扣除费用)的表现。北美迷幻药指数的再平衡在每个日历季度发生。在此情况下,所有符合纳入资格的股票通常按其各自的浮动市值重新加权。Optimi Health在包含中获得1.74%的权重。 该ETF由Horizons ETF Management管理,该公司是一家创新型金融服务公司,提供加拿大最大的交易所交易基金组合之一。Horizons ETF产品系列为不同经验水平的投资者提供多元化的解决方案,以满足他们在不同市场条件下的投资目标。Horizons ETF管理的资产超过190亿美元,有95只ETF在加拿大主要证券交易所上市。Horizons还于2017年推出了首只大麻ETF上市,并继续以新兴行业的ETF引领行业。 Optimi Health的首席执行官迈克·斯蒂尔说:“对Optimi Health的利益相关者来说,纳入ETF是一个重要的里程碑。Horizons ETF给我们带来的认可肯定对公司有利,而增加知名度本身就是一个很大的好处,为新投资者提供了更多的信心和保证。虽然ETF为潜在的新投资者带来了额外的风险敞口,但它也为现有股东创造了价值。我们非常高兴今天宣布这一消息,并期待尽快利用这一绝佳机会。“ 我代表董事会, Optimi健康公司 迈克·施蒂尔 总裁、行政总裁兼董事 关于OPTIMI(CSE:OPTI)(OTC:OPTHF)(FRA:80亿) Optimi正在开发一个复杂的蘑菇品牌,专注于健康和保健市场。Optimi打算以纵向一体化的方式,在其位于不列颠哥伦比亚省普林斯顿的两个设施中种植、提取、加工和分销高质量的功能性蘑菇产品,该设施占地20,000平方英尺,即将完工。为了充分调查蘑菇的科学,该公司通过其全资附属公司Optimi Labs Inc.获得了加拿大卫生部食品和药物条例(FDR)的研究豁免,用于科学目的的Psilocybin和Psilocin。Optimi还根据加拿大麻醉品管制条例申请了经销商许可证,该条例管理Psilocybin和Psilocin配方的拥有、分销、销售、实验室分析和研究与开发。Optimi致力于专家培育和优质生产,并遵守所有适用的法律和管理条例的条款,以确保安全、优质的加拿大真菌生产。 在https://optimiHealth.ca/了解更多信息。 欲了解更多信息,请联系: 投资者关系 电子邮件:[email protected] 电话:+1(778)930-1321 网站:https://optimiHealth.ca/ 前瞻性陈述 本新闻稿包含加拿大证券立法意义内的前瞻性陈述和前瞻性信息(统称为“前瞻性陈述”),涉及Optimi当前的预期和对未来事件的看法。任何表达或涉及对预期、信念、计划、目标、假设或未来事件或表现的讨论的陈述(通常但并非总是通过使用诸如“将可能产生”、“预期”、“预期”、“将继续”、“预期”、“预期”、“相信”、“估计”、“打算”、“计划”、“预测”、“预测”、“战略”、“目标”和“展望”等词语或短语)不是历史事实,可能是前瞻性陈述,可能涉及可能导致实际结果或结果与此类前瞻性陈述所表达的结果或结果有重大差异的估计、假设和不确定性。不能保证这些预期将被证明是正确的,本新闻稿中包括的这些前瞻性陈述不应被过度依赖。这些声明仅限于本新闻稿发布之日。特别但不限于,本新闻稿包含与本公司潜在的纳斯达克上市、经销商的许可证申请、根据本公司的研究豁免建议进行的活动以及与Psilocybin和Psilocin和Optimi的计划、重点和目标相关的相关业务有关的前瞻性陈述。 前瞻性陈述基于多项假设,并受制于多项风险和不确定性,其中许多风险和不确定性是Optimi无法控制的,可能导致实际结果和事件与这些前瞻性陈述中披露或暗示的结果和事件存在重大差异。该等风险及不确定因素包括但不限于新冠肺炎疫情的影响及进展,以及本公司日期为2021年2月12日的最终招股章程中“前瞻性陈述”及“风险因素”项下所载的其他因素。Optimi不承担任何义务更新或修改任何前瞻性陈述,无论是由于新的信息、未来事件或其他原因,除非法律可能要求。新的因素不时出现,而Optimi不可能预测所有这些因素或评估每一个此类因素的影响,或任何因素或因素组合可能导致结果与任何前瞻性陈述所载结果有重大差异的程度。本新闻稿中包含的任何前瞻性陈述均由本警告声明明确限定其全部内容。 本文由CFN Enterprises Inc.(OTCQB:CNFN)发表,该公司是CFN Media的所有者和运营商,CFN Media是行业领先的机构和数字金融媒体网络,致力于新兴的CBD和合法大麻行业。请致电+1(833)420-CNFN了解更多信息。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文